🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInsurance & AccessGoodRx vs manufacturer copay cards — 12 month update

GoodRx vs manufacturer copay cards — 12 month update

maya_sedona Thu, Sep 18, 2025 at 8:27 AM 34 replies 2,001 viewsPage 1 of 7
This thread is more than 8 months old. Information may be outdated. Consider searching for more recent discussions.
maya_sedona
Member
289
1,234
Sep 2024
Sedona, AZ
Sep 18, 2025 at 8:27 AM#1

The list price and the price I actually pay differ by a factor of six depending on which of four routes I use, and none of that is transparent from the outside.

What would genuinely help is knowing what actually works on a prior-authorisation denial, as opposed to the list of things that sound like they should work.

Happy to be told the question itself is wrong.

2 22wanda_boise, NurseAsh_DET
Reply Quote Save Share Report
Dr.GastroMayo
VIP Member
2,345
13,456
Jan 2024
Mayo Clinic, MN
Sep 18, 2025 at 10:32 AM#2
maya_sedona said:
The list price and the price I actually pay differ by a factor of six depending on which of four routes I use, and none of that is transparent from…

Insurance coverage hack for cost and coverage: if your insurance denies brand Wegovy/Ozempic, consider these alternatives:

  1. Prior authorization appeal with peer-to-peer review
  2. Manufacturer copay card (for commercial insurance)
  3. Patient assistance programs (Novo Nordisk, Eli Lilly)
  4. Compounded medication from a 503B pharmacy ($138/month)
  5. Canadian pharmacy (requires prescription, ~40-60% savings)

Don't let cost prevent access to effective treatment. There are options at every price point.

1 21VendorMark
Reply Quote Save Share Report
mark_tokyo
Member
456
1,890
Jun 2024
Tokyo, JP
Sep 18, 2025 at 12:37 PM#3
Dr.GastroMayo said:
Insurance coverage hack for cost and coverage: if your insurance denies brand Wegovy/Ozempic, consider these alternatives: Prior authorization appeal…

Telehealth prescriber review for cost and coverage: I've used 2 different telehealth platforms to get my GLP-1 prescription. Comparison:

FeaturePlatform APlatform BPlatform C
Initial Consult$63$83$0
Monthly Follow-up$33Included$63
Prescription SpeedSame day24-48 hoursSame day
Lab MonitoringRequiredOptionalRequired

I settled on the one that required labs — it shows they care about safety, not just prescribing volume.

50 20LibrarianMeg, bri_stats, pete_manc_UK and 47 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
NurseLeah_Nash
Member
278
1,234
Sep 2024
Nashville, TN
Sep 18, 2025 at 2:42 PM#4
maya_sedona said:
The list price and the price I actually pay differ by a factor of six depending on which of four routes I use, and none of that is transparent from…

Adding a me-too, because a thread of one person's experience is not much use.

Last edited: Sep 18, 2025 at 3:42 PM
49 19Dr.KarenChen, Dr.NateNeph, PharmD_Rodriguez and 46 others
Reply Quote Save Share Report
Dr.RheumBOS
Member
567
2,345
Apr 2024
Boston, MA
Sep 19, 2025 at 3:05 AM#5

Adding the clinical framing, because it changes how the question reads.

maya_sedona said:
...regarding the discontinuation data for cost and coverage...

I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."

Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.

This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.

48 18Dr.PulmRoch, maya_sedona, stefan_berlin and 45 others
Reply Quote Save Share Report
1237

Similar Threads

Prior authorization success: step-by-step guide with templates5 replies
Cigna now covering Zepbound — how I got approved13 replies
Appeal letter template — denied PA for GLP-1 medications4 replies
Mounjaro savings card — manufacturer program changes 202610 replies
Medicare Part D GLP-1 coverage — what's covered in 202610 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register